Crinetics Pharmaceuticals (CRNX) Profit After Tax (2017 - 2026)

Crinetics Pharmaceuticals' Profit After Tax history runs 10 years deep, the most recent figure standing at -$127.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 12404.62% year-over-year to -$127.8 million in Q1 2026; TTM through Mar 2026 was -$258.6 million, a 73.55% decrease from a year earlier, with the FY2025 full-year figure at $902000.0, up 6542.86% from the prior year.
• Profit After Tax slipped to -$127.8 million in Q1 2026 per CRNX's latest filing, from -$329000.0 in the prior quarter.
• Across five years, Profit After Tax topped out at $156.3 million in Q4 2023 and bottomed at -$130.1 million in Q3 2025.
• The 5-year median for Profit After Tax is -$46.0 million (2023), against an average of -$37.7 million.
• Across the five-year window, Profit After Tax surged 421.95% in 2023 and plunged 12404.62% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$48.5 million in 2022, then jumped by 421.95% to $156.3 million in 2023, then sank by 100.69% to -$1.1 million in 2024, then surged by 69.4% to -$329000.0 in 2025, then slumped by 38758.66% to -$127.8 million in 2026.
• Per Business Quant, the three latest CRNX Profit After Tax figures stand at -$127.8 million (Q1 2026), -$329000.0 (Q4 2025), and -$130.1 million (Q3 2025).